FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382011811> ?p ?o ?g. }

• W4382011811 endingPage "1329" @default.
• W4382011811 startingPage "1320" @default.
• W4382011811 abstract "Congenital hyperinsulinism (HI) is a genetic disorder in which pancreatic β-cell insulin secretion is excessive and results in hypoglycemia that, without treatment, can cause brain damage or death. Most patients with loss-of-function mutations in ABCC8 and KCNJ11, the genes encoding the β-cell ATP-sensitive potassium channel (KATP), are unresponsive to diazoxide, the only U.S. Food and Drug Administration–approved medical therapy and require pancreatectomy. The glucagon-like peptide 1 receptor (GLP-1R) antagonist exendin-(9-39) is an effective therapeutic agent that inhibits insulin secretion in both HI and acquired hyperinsulinism. Previously, we identified a highly potent antagonist antibody, TB-001-003, which was derived from our synthetic antibody libraries that were designed to target G protein–coupled receptors. Here, we designed a combinatorial variant antibody library to optimize the activity of TB-001-003 against GLP-1R and performed phage display on cells overexpressing GLP-1R. One antagonist, TB-222-023, is more potent than exendin-(9-39), also known as avexitide. TB-222-023 effectively decreased insulin secretion in primary isolated pancreatic islets from a mouse model of hyperinsulinism, Sur1−/− mice, and in islets from an infant with HI, and increased plasma glucose levels and decreased the insulin to glucose ratio in Sur1−/− mice. These findings demonstrate that targeting GLP-1R with an antibody antagonist is an effective and innovative strategy for treatment of hyperinsulinism. Article Highlights Patients with the most common and severe form of diazoxide-unresponsive congenital hyperinsulinism (HI) require a pancreatectomy. Other second-line therapies are limited in their use because of severe side effects and short half-lives. Therefore, there is a critical need for better therapies. Studies with the glucagon-like peptide 1 receptor (GLP-1R) antagonist, avexitide (exendin-(9-39)), have demonstrated that GLP-1R antagonism is effective at lowering insulin secretion and increasing plasma glucose levels. We have optimized a GLP-1R antagonist antibody with more potent blocking of GLP-1R than avexitide. This antibody therapy is a potential novel and effective treatment for HI." @default.
• W4382011811 created "2023-06-27" @default.
• W4382011811 creator A5000519391 @default.
• W4382011811 creator A5004073544 @default.
• W4382011811 creator A5012497877 @default.
• W4382011811 creator A5013302947 @default.
• W4382011811 creator A5015060415 @default.
• W4382011811 creator A5030045222 @default.
• W4382011811 creator A5032602167 @default.
• W4382011811 creator A5039370145 @default.
• W4382011811 creator A5039971276 @default.
• W4382011811 creator A5045125816 @default.
• W4382011811 creator A5051617679 @default.
• W4382011811 creator A5057974981 @default.
• W4382011811 creator A5063110352 @default.
• W4382011811 creator A5083861011 @default.
• W4382011811 creator A5087863988 @default.
• W4382011811 creator A5092262244 @default.
• W4382011811 date "2023-06-26" @default.
• W4382011811 modified "2023-10-01" @default.
• W4382011811 title "Optimization of a glucagon-like peptide 1 receptor antagonist antibody for treatment of hyperinsulinism" @default.
• W4382011811 cites W1583513661 @default.
• W4382011811 cites W1909310469 @default.
• W4382011811 cites W1977017927 @default.
• W4382011811 cites W1989550908 @default.
• W4382011811 cites W1997986298 @default.
• W4382011811 cites W2013658326 @default.
• W4382011811 cites W2020096098 @default.
• W4382011811 cites W2069640762 @default.
• W4382011811 cites W2073235659 @default.
• W4382011811 cites W2086568807 @default.
• W4382011811 cites W2104214122 @default.
• W4382011811 cites W2107040844 @default.
• W4382011811 cites W2110015701 @default.
• W4382011811 cites W2123427895 @default.
• W4382011811 cites W2126339873 @default.
• W4382011811 cites W2137364215 @default.
• W4382011811 cites W2142903571 @default.
• W4382011811 cites W2145811259 @default.
• W4382011811 cites W2152557643 @default.
• W4382011811 cites W2165848705 @default.
• W4382011811 cites W2168895815 @default.
• W4382011811 cites W2404958982 @default.
• W4382011811 cites W2419951851 @default.
• W4382011811 cites W2618233912 @default.
• W4382011811 cites W2728093281 @default.
• W4382011811 cites W2744291436 @default.
• W4382011811 cites W2766312801 @default.
• W4382011811 cites W2797321538 @default.
• W4382011811 cites W2887064975 @default.
• W4382011811 cites W2907496293 @default.
• W4382011811 cites W2909281962 @default.
• W4382011811 cites W3000083217 @default.
• W4382011811 cites W3014464491 @default.
• W4382011811 cites W3045729180 @default.
• W4382011811 cites W3093042356 @default.
• W4382011811 cites W3130101367 @default.
• W4382011811 cites W3134224424 @default.
• W4382011811 cites W3158589284 @default.
• W4382011811 cites W4200510880 @default.
• W4382011811 cites W4221136197 @default.
• W4382011811 cites W4223603475 @default.
• W4382011811 cites W4226158523 @default.
• W4382011811 cites W4281627591 @default.
• W4382011811 cites W4286267340 @default.
• W4382011811 doi "https://doi.org/10.2337/db22-1039" @default.
• W4382011811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37358194" @default.
• W4382011811 hasPublicationYear "2023" @default.
• W4382011811 type Work @default.
• W4382011811 citedByCount "1" @default.
• W4382011811 countsByYear W43820118112023 @default.
• W4382011811 crossrefType "journal-article" @default.
• W4382011811 hasAuthorship W4382011811A5000519391 @default.
• W4382011811 hasAuthorship W4382011811A5004073544 @default.
• W4382011811 hasAuthorship W4382011811A5012497877 @default.
• W4382011811 hasAuthorship W4382011811A5013302947 @default.
• W4382011811 hasAuthorship W4382011811A5015060415 @default.
• W4382011811 hasAuthorship W4382011811A5030045222 @default.
• W4382011811 hasAuthorship W4382011811A5032602167 @default.
• W4382011811 hasAuthorship W4382011811A5039370145 @default.
• W4382011811 hasAuthorship W4382011811A5039971276 @default.
• W4382011811 hasAuthorship W4382011811A5045125816 @default.
• W4382011811 hasAuthorship W4382011811A5051617679 @default.
• W4382011811 hasAuthorship W4382011811A5057974981 @default.
• W4382011811 hasAuthorship W4382011811A5063110352 @default.
• W4382011811 hasAuthorship W4382011811A5083861011 @default.
• W4382011811 hasAuthorship W4382011811A5087863988 @default.
• W4382011811 hasAuthorship W4382011811A5092262244 @default.
• W4382011811 hasBestOaLocation W43820118111 @default.
• W4382011811 hasConcept C102942909 @default.
• W4382011811 hasConcept C126322002 @default.
• W4382011811 hasConcept C134018914 @default.
• W4382011811 hasConcept C170493617 @default.
• W4382011811 hasConcept C2775858560 @default.
• W4382011811 hasConcept C2776885963 @default.
• W4382011811 hasConcept C2777368190 @default.
• W4382011811 hasConcept C2777391703 @default.
• W4382011811 hasConcept C2777643638 @default.

• next